TRTWORLD — News
20260808 180000 UTC
478 transcript segments
Google Speech-to-Text API Automatic Transcription (Chirp)
Data courtesy of The GDELT Project (https://www.gdeltproject.org/), from the Internet Archive TV News Archive.
Machine transcription. Treat it as a searchable index of what was broadcast, not a verbatim quotation record.

[00:00:03] of
[00:00:09] You're watching TRT World, I'm Yashini Pariachi with the reminder of our
[00:00:13] main headlines. Iran's foreign minister says Terran and Oman
[00:00:17] are very close to deal a new shipping route through the straight of Hormus
[00:00:21] with technical and legal issues largely resolved. Iran's
[00:00:25] revolutionary guard has issued a stark warning though, saying Tehran can
[00:00:29] allow traffic to pass through if the US accepts all of Iran's
[00:00:32] conditions such as lifting the blockade of its
[00:00:35] ports. The reopening
[00:00:38] of the straight of hormos is in fact subject to
[00:00:41] in conditions said by the Islamic Republic of Iran and the
[00:00:45] straight will be reopened on the basis of those
[00:00:48] me conditions, that depends on the extent to which the United States
[00:00:51] accepts the conditions determined by the Islamic Republic of
[00:00:55] Iran. Turkey, Saudi Arabia and
[00:00:58] Pakistan have sign the landmark defense pact in Mecca, pledging
[00:01:02] attack on one will be treated as an attack on all. The Turkish
[00:01:06] President says the deal
[00:01:08] of reaffirms the right to
[00:01:09] a self-defense and is not aimed any country. The deal comes as
[00:01:13] tensions have grown across the region since the war
[00:01:15] started. Russian overnight strikes on Ukraine's
[00:01:19] keive region have killed three people, including
[00:01:22] of a child. Three others were injured when multiple locations just
[00:01:25] outside the capital were also hit. This comes as presidents.
[00:01:30] is in Belgrade on his first official visit to Serbia, one
[00:01:33] of the few countries that have maintained friendly relations with
[00:01:36] Russia. We have now reached an
[00:01:40] agreement with Trump that will grant the licenses, but just imagine if we had received
[00:01:44] them four years ago, we would already be manufacturing patriots for
[00:01:47] everyone, believe me, and Europe, the parts of Europe that
[00:01:51] want and would like to have patriots, anti-ballistic systems and
[00:01:54] missiles would already have them all. I'm absolutely certain of
[00:01:58] that. Authorities say fire at the
[00:02:02] Ilskiy oil refinery in Russia's southern
[00:02:04] of Krasnador region has been extinguished. Russia's defense ministry
[00:02:08] said
[00:02:09] of its air defenses destroy 397 Ukrainian
[00:02:12] drones over multiple regions
[00:02:14] overnight. And typhoon Dolphin is moving
[00:02:18] towards China with the sustained wind speed of 162
[00:02:22] km
[00:02:22] a an hour. It's already triggered heavy rains in
[00:02:25] of northern me Taiwan and passed close to southern Japan where it
[00:02:28] injured five people. and also caused a large scale
[00:02:32] blackout. The news continues here on TRT
[00:02:36] World, be sure to stay with
[00:02:37] us.
[00:02:48] of
[00:02:53] Most of us don't really
[00:02:54] of understand what goes on inside of our bodies until
[00:02:58] something goes wrong. bad knee, a hip that
[00:03:01] a goes out, tissue that doesn't heal properly, and for
[00:03:05] decades the answer was simple: manage it,
[00:03:09] operate on it, and hope for the best,
[00:03:12] of but now there's a new idea that's taking hold that the body
[00:03:16] doesn't need just fixing, that it might actually possess the tools to fix
[00:03:20] itself. what used to be science fiction is now a
[00:03:23] reality?
[00:03:36] in
[00:03:49] Stem a cells: you've probably heard the term being thrown
[00:03:53] around, in headlines,
[00:03:55] of in wellness clinics, maybe even
[00:03:57] in a conversation
[00:03:58] of with a friend who's... by their medical benefits.
[00:04:02] a report that doctor has found a way to grow a new wind pipe for
[00:04:06] patients with cancer. the first human trials of embryonic stem
[00:04:10] cells are now underway. a brand new law in tennessee
[00:04:13] of is
[00:04:13] of expanding the use of stem cells for medical treatment. we're back now with the
[00:04:17] controversy over stem cell clinics, but the truth
[00:04:21] is very few actually understand what they are,
[00:04:24] or why scientists consider them one
[00:04:27] of of the most significant frontiers. in modern
[00:04:30] medicine. Here's the simple version. Every
[00:04:34] organ in our body is built from billions of specialized
[00:04:38] cells. Skin cells repair our skin, muscle
[00:04:42] cells help us move, nerve cells carry signals throughout
[00:04:46] the body. But stem cells are different. They are
[00:04:49] found early embryos and naturally throughout
[00:04:52] of our bodies,
[00:04:54] me including in in bone marrow, blood and fat tissue. They
[00:04:57] can also be collected from umbilical... cored blood and cored tissue
[00:05:01] after birth. Unlike ordinary cells,
[00:05:05] stem cells haven't yet committed to becoming a specific
[00:05:09] cell type. They have the remarkable ability to... develop into
[00:05:13] many different types of cells, making them one the body's
[00:05:17] most versatile building blocks. when injury or
[00:05:20] disease damages tissue, stem cells can travel to the
[00:05:24] affected area, helping support the body's natural repair
[00:05:28] process. scientists are now learning how to
[00:05:31] isolate, grow and return these cells to patients in an
[00:05:35] effort to improve healing and recovery. today,
[00:05:39] stem cell therapies are already being used to treat. certain blood
[00:05:43] disorders, while researchers are studying their potential in areas
[00:05:46] ranging from orthopedics and neurology to optalmology and
[00:05:50] regenerative medicine. But successful stem cell
[00:05:54] therapy requires much more than science. It
[00:05:58] depends on an entire ecosystem of researchers,
[00:06:01] laboratories, hospitals, biobanks and
[00:06:04] regulators working together, and that's exactly the
[00:06:08] system Turkia is now trying to build.
[00:06:13] that entire chain, research, regulation,
[00:06:16] collaboration has to start somewhere in Turkey,
[00:06:20] one the places it starts is here at Onkim, this
[00:06:24] research center operates at the foundation of this
[00:06:27] ecosystem, but before a single treatment can happen,
[00:06:31] someone has to know exactly what they're dealing with at the cellular
[00:06:35] level, and that diagnostic work is where onkim has built
[00:06:39] its name,
[00:07:13] how you can balance
[00:07:17] business sustainability
[00:07:20] and
[00:07:31] the most important factor
[00:07:33] in ensuring sustainability is creating real value for
[00:07:37] people as
[00:07:38] in
[00:07:43] benefits, sustainability follows naturally.
[00:07:47] At Onkim, our focus is not soly financial. We place people at
[00:07:51] the center of everything we do. Our goal is to generate
[00:07:55] positive outcomes for patients while delivering those benefits in
[00:07:59] the most cost-effective way possible. In the past,
[00:08:03] many advanced molecular diagnostics and precision medicine
[00:08:06] services in Turkia relied heavily on overseas
[00:08:10] providers because domestic capability. were limited, as
[00:08:14] result, costs were significantly higher.
[00:08:17] today, by carrying out these services within our own company
[00:08:21] and within our own country, we're creating opportunities not
[00:08:25] only at the regional level, but also a global
[00:08:29] scale. of course, success requires more than the efforts of a single
[00:08:33] company, strong collaboration between the private sector and
[00:08:36] government is essential. innovation must be supported
[00:08:40] by timely and effective.
[00:08:52] and stem cell technology only means something if it can actually deliver precision treatment
[00:08:56] patient by patient. wanted to see how that promise
[00:09:00] holds up in the lab, because before a doctor can choose a
[00:09:04] treatment, something has to happen first, someone has to
[00:09:08] decode what's actually going wrong at the cellular level.
[00:09:12] this is: where modern medicine starts to look less like a
[00:09:15] playbook and more like fingerprint.
[00:09:18] increasingly treatment isn't built for disease, it's built for
[00:09:22] a specific patient down to the molecular detail their
[00:09:26] condition. that requires advanced genetic
[00:09:29] testing. to understand how that actually works, i spoke
[00:09:33] to punard, onkim's director.
[00:09:37] advanced diagnostic methods, particularly molecular and
[00:09:41] genetic testing, reached a very different level, especially in the field
[00:09:45] of cancer. Today, cancers and tumors are no
[00:09:49] longer analyzed solly based on their structural or standard
[00:09:52] pathological characteristics. We now conduct a wide
[00:09:56] range of analyses related to the molecular and genetic
[00:09:59] makeup of cancers and tumors. Not long
[00:10:03] ago, many patients with the same type of cancer received
[00:10:07] exactly the same treatment, but doctors often saw
[00:10:11] very different results. Today, scientists
[00:10:15] know that the two patients with the same cancer can have very different
[00:10:19] genetic mutations driving their disease, using
[00:10:22] advanced genetic and molecular test. laboratories can
[00:10:26] identify those mutations and build
[00:10:29] a detailed profile of each patient's cancer.
[00:10:33] That information helps doctors choose therapies that are more closely matched
[00:10:37] to each individual patient rather than relying a
[00:10:41] one size fits all approach. The result can be
[00:10:45] faster treatment, fewer side effects and a greater chance
[00:10:48] of success. It's a shift that's transforming how
[00:10:52] diseases like cancer are diagnosed. and
[00:10:55] treated, since we are no longer
[00:10:58] focusing only on the pathological characteristics of cancer,
[00:11:02] but to also its molecular features, we have made substantial
[00:11:06] progress in treatment, it has allowed cancer therapy to become
[00:11:10] much more personalized. can you talk to a little bit about what
[00:11:14] type of technologies and platforms are at the core
[00:11:18] of this lab?
[00:11:22] when onkim stemcell technologies was founded in
[00:11:25] 2005, it was established as a GMP laboratory
[00:11:29] focused soy on cold blood banking. Over the years, however,
[00:11:33] stemcell technologies experienced significant global
[00:11:36] advances. As onkim evolved, we expanded beyond cold
[00:11:40] blood banking to include the banking of stem cells obtained from
[00:11:43] various tissues as well as their production and delivery to patients
[00:11:47] whenever needed. We therefore collaborate closely with a wide
[00:11:51] range of medical specialties, hospitals and physicians.
[00:12:03] or you went under the knife of a surgeon, but what if healing
[00:12:06] didn't require going to a pharmacy or the hands of a
[00:12:10] surgeon?
[00:12:11] what if healing came from within if we could activate the cells
[00:12:15] that knew exactly what to fix? that
[00:12:19] idea healing from within has a name
[00:12:23] regenerative medicine and and it represents
[00:12:26] genuine shift in how we think about treatment, instead of
[00:12:30] only managing symptoms or replacing damaged tissue,
[00:12:34] the goal is to restore the body's own ability to repair
[00:12:38] itself. stem cells matter most precisely
[00:12:42] in that gap, in injuries and conditions where
[00:12:45] conventional treatment hits the ceiling, where surgery carries
[00:12:49] real risk or where the body simply needs support
[00:12:53] to do what it was already. built to do, that's the exact
[00:12:57] territory greentech was built to operate in,
[00:13:00] founded with focus on stem cell therapies and joint health, the
[00:13:04] company has since expanded its ambitions
[00:13:07] considerably. when we say regenerative medicine, we doesn't mean that
[00:13:11] we have to ignore or we have to get rid the medicine itself, because the medicine itself
[00:13:15] is something that we cannot, it's indispensable in our in our
[00:13:19] our life, because basically we have some treat some diseases like chronic
[00:13:23] diseases or some other diseases that we need to do a surger or operation for that,
[00:13:27] however regenerative medicines is kind of based or we focus on that
[00:13:31] regenerative medicine when we want to use we want to preserve
[00:13:34] or we want to just decrease the progression the disease itself, or for
[00:13:38] example we want to use it or think about it with patients that
[00:13:42] cannot be cannot enter to the or itself, for
[00:13:45] example older people or children or pregnant woman
[00:13:49] for example, that's why we try to go to the regenerative medicine and specifically in
[00:13:53] the athletes or sports medicine for. for example, me, for example, i would
[00:13:57] never like to have a surgery in my age, especially in the osteoarthritis level
[00:14:01] or any orthopedic level, that's why we try to go to the orthopedic or to
[00:14:04] the regenerative medicine field, like can do stem cell therapy, can do
[00:14:08] maybe PRP, which is at the beginning, what we can do as regenerative
[00:14:12] medicine to avoid and escape as much as possible from the
[00:14:16] or which is the surgery. i think you're talking about endless
[00:14:19] possibilities, i think one the first things that comes to mind and probably
[00:14:23] one the biggest concerns. in biotech in
[00:14:27] general is uh regulation and
[00:14:30] trust, yes, how do you balance
[00:14:33] innovation with patient safety?
[00:14:37] most most the challenging topics to be honest in our work, but we try to basically
[00:14:41] move with the science, so our main base and our main rule is to go and follow
[00:14:45] up the science first. for example, let's let me give you an example, when we talk about
[00:14:49] stem cells, so we need to to know all the information about stem
[00:14:53] cells and the scientific background about stem. cells and how can we use them medically over
[00:14:57] the humans over the human first and then accordingly think
[00:15:01] and see how can we apply them and we like because the regulatory part is really
[00:15:04] important some of so many like we have so many possibilities or
[00:15:08] treatments that we can use them and they can be logical however they are unethical
[00:15:12] or we cannot ethically use them over human that's why we try to focus more in
[00:15:16] the see the possibility these medicines or this options
[00:15:20] if we can do them over humans and accordingly and go over the
[00:15:23] treatment. Every breakthrough in medicine
[00:15:27] begins with research, but very few ever become
[00:15:31] actual products doctors can use a real
[00:15:34] patient. That gap between discovery. in
[00:15:37] delivery is far less forgiving than in most other
[00:15:41] industries. turning laboratory inside into something
[00:15:45] deployable takes more than good science. takes
[00:15:48] infrastructure, partnerships and people whose entire
[00:15:52] job is closing the distance. actually
[00:15:55] it is not easy to produce the real products
[00:15:59] from the lab to market,
[00:16:02] but therefore we get some help from
[00:16:06] the industry. therefore we uh talking about
[00:16:09] the green tech biotechnology company therefore
[00:16:13] involved our studies, one other thing that I think
[00:16:17] might be difficult is when you're looking around this
[00:16:20] laboratory uh there are scientists, there are engineers,
[00:16:24] there are clinicians, how do you
[00:16:27] coordinate everything, because
[00:16:31] not everything it's not a single discipline field, yeah
[00:16:34] yes definitely you are right, we build... here is
[00:16:38] very big ecosystems,
[00:16:40] you know one uh colleagues and also students come from the
[00:16:44] engineering part, but engineer part also has different
[00:16:47] departments, such as not only the
[00:16:51] meter science, bio engineering and bio and also mechanical
[00:16:54] engineering, we can also involve the computer engineering,
[00:16:58] this is the field the health, but we need the
[00:17:02] uh computer engineering also involved our studies, not only
[00:17:06] engineering part we... and also had to from the
[00:17:09] clinicians, from the uh medicine and
[00:17:13] also comes from the other disciplines,
[00:17:17] fundamental science, biology, chemical,
[00:17:20] chemistry and also physics as well,
[00:17:24] research, regulation, production, at some
[00:17:28] point all of this has to face the most important test of
[00:17:32] all, does it actually work a real patient? that's
[00:17:35] why we came here to chump secure a hospital in Istanbul
[00:17:39] where stem cell technology has moved out the lab and into
[00:17:43] daily clinical practice. This is one the places in
[00:17:47] Turkia's healthcare system where regenerative therapy is
[00:17:51] no longer just theoretical. It's a
[00:17:54] Wednesday afternoon, it's a scheduled procedure. It's
[00:17:58] a patient hoping for different outcome than the one
[00:18:02] conventional treatment offered to them. So, what is stem
[00:18:05] cell therapy actually offer?
[00:18:11] Before I was diagnosed with leukemia, I had no idea my treatment would be
[00:18:15] given through ivy drip. It turned out to be very simple
[00:18:19] process. Once I started treatment, I began to see how
[00:18:23] much the medication was affecting my body. I used to be very
[00:18:27] social person, but there were times when I had
[00:18:29] to be hospitalized. My life changed completely. After my
[00:18:33] stem so transplant, I realized how many things I had taken for.
[00:18:38] It made me truly appreciate the little things in
[00:18:40] life. It's not only the patients who
[00:18:44] benefit, for doctors, this technology represents something
[00:18:48] more than new tool in the kit. It's an expansion of what
[00:18:52] they're capable of treating, and of course how skills that used
[00:18:56] to stop at the limits of surgery now extend into the
[00:18:59] body's own regenerative capacity. Actually,
[00:19:03] we have two main sources for stem cells for ' this
[00:19:07] stem cell transplantation, firstly this
[00:19:11] is the peripherical stem cells and the second one is
[00:19:15] bonne marrow, bone marrow is great, yeah,
[00:19:18] and usually our
[00:19:21] patients need a peripheric stem cell source and
[00:19:25] we use mostly the peripherical stem cell source.
[00:19:29] think i have to ask you this question too, with the way things are
[00:19:33] advancing, take me five years down line, 10 years
[00:19:37] down. where are we in the medical industry when it comes to stem
[00:19:40] cells? i think that we have also so uh
[00:19:43] many new ways to obtain a cure for those
[00:19:47] patients. stem cell transplantation is very
[00:19:51] complicated process for our patients. we can also
[00:19:55] observe GVHD, prophers leukemia effects and and
[00:19:59] also some mortal adverse effects in stem cell transplantation.
[00:20:03] after stem cell transplant transplantation '
[00:20:07] and our patient had also grade 2-3
[00:20:11] GVHD after stump cell transplantation and it is so
[00:20:14] complicated to overcome this GVHD period and
[00:20:18] I think we have we will have new
[00:20:21] treatment methods in near
[00:20:25] future. Every stem cell treatment begins with
[00:20:28] collection, depending on the therapy, stem cells can be
[00:20:32] obtained from bone marrow, fat tissue or umbilical
[00:20:36] core blood and tissue after birth. once
[00:20:40] inside the laboratory, every sample undergoes extensive
[00:20:43] testing. scientists isolate the stem cells,
[00:20:47] verifying their quality and ensure the... meet strict safety
[00:20:51] standards before they can be used. some cells are
[00:20:55] prepared for immediate treatment, others are
[00:20:58] cryo-preserved and stored in liquid nitrogen at nearly
[00:21:02] minus 196° celsius, where they can remain
[00:21:06] viable for years. every sample is fully
[00:21:10] traceable throughout the entire process, from collection and
[00:21:13] storage to transportation and clinical use.
[00:21:17] every step is carefully documented and and monitored.
[00:21:21] when a patient needs treatment, the stem cells are retrieved,
[00:21:25] transported under carefully controlled conditions, and prepared for
[00:21:29] clinical use. it's the final step a process that can
[00:21:32] begin years before a patient ever walks into a
[00:21:36] hospital. what that graphic just walk
[00:21:39] through, collection, testing, storage at nearly minus
[00:21:43] 200° celsius isn't a foot note. it's the
[00:21:47] entire infrastructure that makes everything. possible,
[00:21:51] long before a patient ever walks into a hospital, their
[00:21:54] treatment may already be years in the making, and by
[00:21:58] that I mean sitting quietly in liquid
[00:22:01] nitrogen, waiting. This is the world of
[00:22:05] biobanking, the not too glamorous, highly
[00:22:08] disciplined work of handling biological material so that it's
[00:22:12] ready exactly when it's needed. It's the world that
[00:22:16] Stembio operates in.
[00:22:20] Today we use stem cell therapies in many different areas, for
[00:22:24] example, we use them to stimulate and accelerate
[00:22:27] healing in chronic wounds, delayed fracture healing, or
[00:22:31] cases where healing is impaired. Both stem cell
[00:22:35] therapies themselves and stem-cell derived products such
[00:22:38] as exezomes are widely used for these
[00:22:42] purposes. What do they do? They enable communication
[00:22:45] between cells. When we administer exozomes from outside the body.
[00:22:50] Our goal is to restore that cellular communication and
[00:22:54] stimulate the body's natural healing processes once
[00:22:56] again. I think when you look at today, lot of people are
[00:23:00] talking about how much artificial intelligence is going to change
[00:23:04] our lives, and while some part of us that says, all right,
[00:23:08] it's going to improve our lives drastically, some part
[00:23:11] is fearful. Let ask you about regenerative
[00:23:15] medicine, take me five years down the line, where are we in five
[00:23:19] years? where regenerative medicine stands today already
[00:23:22] tells us something important: these therapies have
[00:23:26] demonstrated a strong safety profile. We now have
[00:23:29] approximately 25 to 30 years of accumulated data showing that
[00:23:33] these treatments can be administered safely and
[00:23:36] effectively. Moreover, many recent clinical
[00:23:40] studies have demonstrated meaningful clinical
[00:23:43] benefits. One the biggest expectations patients and the
[00:23:47] general public have is not simply living longer. but
[00:23:50] extending their healthy lifespan. For this reason,
[00:23:54] regenerative therapies are becoming increasingly popular in the field
[00:23:58] of longevity medicine. We are receiving interest and
[00:24:01] demand from all over the world. Anti-aging
[00:24:05] applications in particular have attracted tremendous
[00:24:08] attention. Discoveries like these have significantly
[00:24:12] expanded the possibilities for cellular therapies in healthy
[00:24:16] aging and age-related interventions. When these.
[00:24:20] supportive treatments are administered regularly and at appropriate
[00:24:24] intervals, they may contribute to healthier
[00:24:26] aging. one way to think about this is the state of
[00:24:30] chronic inflammation. the goal is to continuously control and
[00:24:34] slow down that
[00:24:35] process.
[00:24:39] as exciting as the science sounds, every researcher we've
[00:24:43] spoken to keeps returning to that same word:
[00:24:46] regulation, because the science can only move - fast
[00:24:50] as trust allows it to. the real challenge isn't
[00:24:54] discovering what is possible, it's actually preserving the
[00:24:58] integrity of that discovery long enough for it to last,
[00:25:02] earning trust, addressing legitimate fears and
[00:25:06] separating evidence from hype. that tension
[00:25:10] between possibility and caution is exactly where
[00:25:13] durmush
[00:25:16] is that? buradaki anahtar kelime aslında regulasyon.
[00:25:20] is regulation. In medicine, we're obliged to follow the
[00:25:24] principle of first do no harm. Cellular
[00:25:27] therapies, especially over the last 25 to 30 years,
[00:25:31] initially emerged as treatments aimed at replacing
[00:25:35] biological deficiencies. Today, however, they've evolved
[00:25:39] into therapies that can potentially support almost any tissue
[00:25:42] or organ in the body, either directly or
[00:25:46] indirectly. That said, there are areas where scientif.
[00:25:50] research and therapeutic applications overlap, well
[00:25:54] still remaining clearly distinct, this is where regulations
[00:25:57] become extremely important and in fact
[00:26:01] work to -
[00:26:24] Our organization manages multiple disciplines within biological medicine,
[00:26:27] both at the research level and at the clinical treatment
[00:26:31] level through and integrated operational
[00:26:34] framework, personalized medicine is very broad umbrella that
[00:26:38] encompasses biological therapies, including cellular
[00:26:42] therapies. the key question we ask is, is this individual
[00:26:45] a suitable candidate for this therapy? if so,
[00:26:49] which treatment protocol should be used, at what stage, and
[00:26:53] with which cellular therapy tool or approach? when we
[00:26:57] successfully bring all these components together, and when we look ahead,
[00:27:00] 5, 10 or 15. years into the future, we believe we'll
[00:27:04] see a strong upward trend in outcomes and
[00:27:08] adoption, and it's a trend that will all witness
[00:27:11] together.
[00:27:16] step back and what you start to see isn't a handful of separate
[00:27:20] companies, it's an entire ecosystem,
[00:27:23] advanced diagnostics decoding everything that could go
[00:27:27] wrong, and doing this a cellular level,
[00:27:30] healthcare across every link in that chain is becoming more
[00:27:34] precise, more individualized, less about a
[00:27:38] specific protocol, and more about a treatment built around
[00:27:42] one person's specific biology, and it's
[00:27:45] moving faster than most people realize, which
[00:27:49] leaves an open question, one that every scientist in the
[00:27:53] story circled back to in their own way: how do you make
[00:27:56] sure this technology is used ethically? how do you earn the
[00:28:00] public's trust without over? selling what still needs to be
[00:28:04] proven? those questions don't have a direct
[00:28:07] answer, at least not yet, but for the
[00:28:11] first time the people working on them have real tools
[00:28:15] and real evidence to work with. from
[00:28:19] storing cells for future use to scientists developing
[00:28:22] specific therapies to doctors using them on real
[00:28:26] patients. the fact the matter is that we're experiencing
[00:28:29] tectonic shift that medicine... isn't just about
[00:28:33] curing the disease, it's about regeneration,
[00:28:37] and the promises are powerful that the body can heal
[00:28:41] itself, that not all injuries require surgeries, and that
[00:28:44] healing is a very natural process, but like
[00:28:48] every frontier, the science needs to catch up with the
[00:28:52] ambition, and it will. well,
[00:28:55] that's it for this edition of nexttech from much younger and healthier
[00:28:59] feeling Adijana. thanks for watching. And we'll see you next
[00:29:03] time,
[00:29:24] intuitive, inclusive, informative,
[00:29:28] from the remotest reaches to the teaming
[00:29:30] Metropolises, The world is one click
[00:29:33] away.
[00:29:35] TRTworld.com.
[00:29:40] The Balkans is at the crossroads of history.
[00:29:44] Foreign influence has always weighed heavily on the
[00:29:47] people. The war in Ukraine
[00:29:51] has tested the fragile
[00:29:53] car.
[00:29:58] As global powers consider their next steps, few
[00:30:01] takento. consideration what the people here
[00:30:04] want
[00:30:09] across the balcans on TRT
[00:30:12] World.
[00:30:28] Jewish Americans are at the center the country's shifting views on.
[00:30:34] The Jewish people and the zionists are not the same. The state of Israel is
[00:30:38] here for a political movement to build support their
[00:30:42] nationalism. Benjamin Netanyahu is not welcome in New York
[00:30:45] City. So
[00:30:49] it's important to have like Jewish voices out there cuz unfortunately we live a
[00:30:52] very racist world where people listen to as a
[00:30:56] white Jewish man more than they will listen to a palestinan who's actually lost.